EGFR and head and neck cancer: In the present study, we evaluated the interest of inhibiting the EGFR/mTOR/HIF-1 axis to radiosensitize head and neck cancer cells based on combining the anti-EGFR monoclonal antibody cetuximab and the mTOR inhibitor rapamycin.